Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/112773
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Nanosecond laser therapy reverses pathologic and molecular changes in age-related macular degeneration without retinal damage |
Author: | Jobling, A. Guymer, R. Vessey, K. Greferath, U. Mills, S. Brassington, K. Luu, C. Aung, K. Trogrlic, L. Plunkett, M. Fletcher, E. |
Citation: | The FASEB Journal, 2015; 29(2):696-710 |
Publisher: | Federation of American Societies for Experimental Biology |
Issue Date: | 2015 |
ISSN: | 0892-6638 1530-6860 |
Statement of Responsibility: | A.I. Jobling, R.H. Guymer, K.A. Vessey, U. Greferath, S.A. Mills, K.H. Brassington, C.D. Luu, K.Z. Aung, L. Trogrlic, M. Plunkett and E.L. Fletcher |
Abstract: | Age-related macular degeneration (AMD) is a leading cause of vision loss, characterized by drusen deposits and thickened Bruch's membrane (BM). This study details the capacity of nanosecond laser treatment to reduce drusen and thin BM while maintaining retinal structure. Fifty patients with AMD had a single nanosecond laser treatment session and after 2 yr, change in drusen area was compared with an untreated cohort of patients. The retinal effect of the laser was determined in human and mouse eyes using immunohistochemistry and compared with untreated eyes. In a mouse with thickened BM (ApoEnull), the effect of laser treatment was quantified using electron microscopy and quantitative PCR. In patients with AMD, nanosecond laser treatment reduced drusen load at 2 yr. Retinal structure was not compromised in human and mouse retina after laser treatment, with only a discrete retinal pigment epithelium (RPE) injury, and limited mononuclear cell response observed. BM was thinned in the ApoEnull mouse 3 mo after treatment (ApoEnull treated 683 ± 38 nm, ApoEnull untreated 890 ± 60 nm, C57Bl6J 606 ± 43 nm), with the expression of matrix metalloproteinase-2 and -3 increased (>260%). Nanosecond laser resolved drusen independent of retinal damage and improved BM structure, suggesting this treatment has the potential to reduce AMD progression. |
Keywords: | Vision loss; drusen; Bruch’s membrane; matrix metalloproteinase |
Rights: | © FASEB |
DOI: | 10.1096/fj.14-262444 |
Grant ID: | http://purl.org/au-research/grants/nhmrc/1038220 http://purl.org/au-research/grants/nhmrc/1061418 http://purl.org/au-research/grants/nhmrc/1061419 http://purl.org/au-research/grants/nhmrc/529905 |
Published version: | http://dx.doi.org/10.1096/fj.14-262444 |
Appears in Collections: | Aurora harvest 3 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.